BioCentury | Apr 2, 2020
Distillery Therapeutics

CDC42BPA inhibition for high-grade serous ovarian carcinoma

DISEASE CATEGORY: Cancer INDICATION: Ovarian cancer Inhibition of CDC42BPA alone or in combination with carboplatin and PAK1 inhibition could treat high-grade serous ovarian carcinoma (HGSOC). Among 594 patient tumors, 44% of the samples had genomic...
BC Innovations | Nov 30, 2018
Targets & Mechanisms

Adhesion targets emerge at ASH 2018

The next wave of targets in blood cancers and hematology will come from adhesion molecules, innate immune cells and regulators of gene expression, according to BioCentury’s analysis of emerging targets at ASH 2018. BioCentury’s analysis...
BC Week In Review | May 25, 2018
Company News

Antengene adds bundle of Karyopharm assets to pipeline

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) granted cancer company Antengene Corp. (Shanghai, China) exclusive Asian rights to four compounds, significantly building out the Chinese company's clinical pipeline. Antengene will develop and commercialize Karyopharm's selinexor (KPT-330) and eltanexor...
BC Extra | May 24, 2018
Company News

Antengene fills pipeline with Karyopharm deal

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) granted cancer company Antengene Corp. (Shanghai, China) exclusive Asian rights to four compounds, significantly building out the Chinese company's clinical pipeline. Antengene will develop and commercialize Karyopharm's selinexor (KPT-330) and eltanexor...
BC Innovations | Mar 20, 2018
Distillery Techniques

Assays and screens

TECHNOLOGY: Cellular assays CRISPR-based screening in human cells could help identify the therapeutic targets of small molecules. The method involved three steps: generating in-frame mutations in human cell lines by engineering them to express CRISPR-associated...
BC Innovations | Mar 7, 2018
Distillery Therapeutics

Gastrointestinal

INDICATION: Colitis Patient sample and mouse studies suggest inhibiting PAK1 and PAK2 could help treat colitis. In samples from patients with inflammatory bowel disease (IBD), levels of a PAK1-induced gene signature were higher in inflamed...
BC Innovations | Nov 6, 2017
Distillery Therapeutics

Cancer

INDICATION: Melanoma Patient sample, cell culture and mouse studies suggest inhibiting PAK1 or PAK4 could help treat drug-resistant BRAF-mutant melanoma. In tumor samples from metastatic melanoma patients, high primary tumor levels of PAK1 were associated...
BC Innovations | Sep 1, 2016
Distillery Therapeutics

Therapeutics: Yes-associated protein 1 (YAP1; YAP); p21 protein (Cdc42 Rac)-activated kinase 1 (PAK1)

Hepatic disease INDICATION: Liver fibrosis Cell culture and mouse studies suggest inhibiting YAP1 or PAK1 could help treat liver fibrosis. In activated rat primary liver myofibroblasts, the YAP1 inhibitor Visudyne verteporfin or a PAK1 inhibitor...
BC Week In Review | Jul 11, 2016
Clinical News

KPT-9274: Phase I started

Karyopharm began an open-label, dose-escalation, dose-expansion, U.S. Phase I trial to evaluate oral KPT-9274 with or without extended-release niacin given 3 times a week every other day of a 28-day cycle in about 175 patients....
BC Week In Review | May 30, 2016
Company News

Cancer Research UK, Pangaea Biotech deal

Pangaea and Cancer Research UK’s commercialization and development arm, Cancer Research Technology (CRT), partnered to develop CRT’s p21 protein (Cdc42 Rac)-activated kinase (PAK) inhibitors for cancer. Both partners will be responsible for lead optimization, and...
Items per page:
1 - 10 of 26